Search Results - "Armand, J. P."

Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy by Italiano, A., Massard, C., Bahleda, R., Vataire, A.-L., Deutsch, E., Magné, N., Pignon, J.-P., Vassal, G., Armand, J.-P., Soria, J.-C.

“…Background: The oncology community usually perceives phase I oncology trials as associated with poor or limited benefits and substantial risks. There is scarce…”
Get full text

Pharmacokinetic and pharmacodynamic end points with anti-VEGFR: the more it hurts, the more it works? by Mir, O., Dumont, S., Armand, J.-P.

Get full text

Nasopharyngeal carcinomas: an update by Spano, J.-P., Busson, P., Atlan, D., Bourhis, J., Pignon, J.-P., Esteban, C., Armand, J.-P.

“…Among the group of head and neck cancers, nasopharyngeal carcinomas (NPC) represent a distinct entity in terms of their epidemiology, clinical presentation,…”
Get full text

Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials by Bernard-Tessier, A., Baldini, C., Castanon Alvarez, E., Ammari, S., Martin Romano, P., Champiat, S., Hollebecque, A., Postel-Vinay, S., Varga, A., Bahleda, R., Gazzah, A., Michot, J.-M., Ribrag, V., Armand, J.-P., Marabelle, A., Soria, J.-C., Massard, C.

Get full text

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers by Soria, J.C, Massard, C, Magné, N, Bader, Th, Mansfield, C.D, Blay, J.Y, Bui, B.N, Moussy, A, Hermine, O, Armand, J.P

“…Abstract Background Masitinib is a tyrosine kinase inhibitor with a pre-clinical profile suggesting greater affinity and selectivity in vitro for the wild-type…”
Get full text

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety by Gomez-Roca, C.A., Lacroix, L., Massard, C., De Baere, T., Deschamps, F., Pramod, R., Bahleda, R., Deutsch, E., Bourgier, C., Angevin, E., Lazar, V., Ribrag, V., Koscielny, S., Chami, L., Lassau, N., Dromain, C., Robert, C., Routier, E., Armand, J.P., Soria, J.-C.

“…Sequential tumour biopsies are of potential interest for the rational development of molecular targeted therapies. From June 2004 to July 2009, 186 patients…”
Get full text

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors by Soria, J.-C., Cortes, J., Massard, C., Armand, J.-P., De Andreis, D., Ropert, S., Lopez, E., Catteau, A., James, J., Marier, J.-F., Beliveau, M., Martell, R.E., Baselga, J.

“…We studied the safety, tolerability, and recommended dose of BMS-599626, an orally bioavailable inhibitor of the human epidermal growth factor receptor (HER)…”
Get full text

Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients by De Crevoisier, R, Bourhis, J, Domenge, C, Wibault, P, Koscielny, S, Lusinchi, A, Mamelle, G, Janot, F, Julieron, M, Leridant, A M, Marandas, P, Armand, J P, Schwaab, G, Luboinski, B, Eschwege, F

“…To review our experience using full-dose external reirradiation given with a curative intent for patients with unresectable head and neck carcinoma (HNC)…”
Get more information

Nasopharyngeal carcinoma and therapeutic management: the place of chemotherapy by Guigay, J., Temam, S., Bourhis, J., Pignon, J.-P., Armand, J.-P.

Get full text

Immune-related adverse events with immune checkpoint blockade: a comprehensive review by Michot, J.M, Bigenwald, C, Champiat, S, Collins, M, Carbonnel, F, Postel-Vinay, S, Berdelou, A, Varga, A, Bahleda, R, Hollebecque, A, Massard, C, Fuerea, A, Ribrag, V, Gazzah, A, Armand, J.P, Amellal, N, Angevin, E, Noel, N, Boutros, C, Mateus, C, Robert, C, Soria, J.C, Marabelle, A, Lambotte, O

“…Abstract Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in which therapeutic agents are used to target immune cells…”
Get full text

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy by Raymond, E, Faivre, S, Armand, J P

“…Increasing knowledge of the structure and function of the epidermal growth factor receptor (EGFR) subfamily of tyrosine kinases and of their role in the…”
Get full text

Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours by Bennouna, J., Fumoleau, P., Armand, J.-P., Raymond, E., Campone, M., Delgado, F.-M., Puozzo, C., Marty, M.

“…Background: Vinflunine is a novel vinca alkaloid obtained by semi-synthesis using super-acidic chemistry to selectively introduce two fluorine atoms at the 20′…”
Get full text

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours by Boven, E, Massard, C, Armand, J P, Tillier, C, Hartog, V, Brega, N M, Countouriotis, A M, Ruiz-Garcia, A, Soria, J C

“…Background: Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumour and antiangiogenic activity. We investigated the safety and…”
Get full text

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin by Ducreux, M., Rougier, P., Fandi, A., Clavero-Fabri, M.-C., Villing, A.-L., Fassone, F., Fandi, L., Zarba, J., Armand, J.-P.

“…Background The combination of 5-fluorouracil (5-FU) and cisplatin has shown great activity in many different types of tumour with an in vitro synergistic…”
Get full text

Phase I–II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma by Faivre, S., Le Chevalier, T., Monnerat, C., Lokiec, F., Novello, S., Taieb, J., Pautier, P., Lhommé, C., Ruffié, P., Kayitalire, L., Armand, J.-P., Raymond, E.

“…Background: The aim of this study was to determine the toxicity profile, the recommended dose (RD) and the pharmacokinetic parameters, and to evaluate the…”
Get full text

Molecular targeting: targeting angiogenesis in solid tumors by Soria, J.-C., Fayette, J., Armand, J.-P.

Get full text

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma by RAYMOND, E, FABBRO, M, VERMILLET, L, ARMAND, J. P, BOIGE, V, RIXE, O, FRENAY, M, VASSAL, G, FAIVRE, S, SICARD, E, GERMA, C, RODIER, J. M

“…To assess the antitumour activity and safety profile of irinotecan and its pharmacokinetic interactions with anticonvulsants in patients with glioblastoma…”
Get full text

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck by PIVOT, X, RAYMOND, E, NIYIKIZA, C, JOHNSON, R, LATZ, J, SCHNEIDER, M, LAGUERRE, B, DEGARDIN, M, CALS, L, ARMAND, J. P, LEFEBVRE, J. L, GEDOUIN, D, RIPOCHE, V, KAYITALIRE, L

“…This phase II study determined response rate of patients with locally advanced or metastatic head and neck cancer treated with pemetrexed disodium, a new…”
Get full text

Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials by RIVORY, L. P, HAAZ, M.-C, CANAL, P, LOKIEC, F, ARMAND, J.-P, ROBERT, J

“…Irinotecan (CPT-11) is an analogue of 20(S)-camptothecin with promising activity against several tumor types. In patients, CPT-11 is metabolized to…”
Get full text

Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors by Vera, K., Djafari, L., Faivre, S., Guillamo, J.-S., Djazouli, K., Osorio, M., Parker, F., Cioloca, C., Abdulkarim, B., Armand, J.-P., Raymond, E.

“…Background: Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150–200 mg/m2/day on days 1–5 every 4 weeks…”
Get full text